Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.

ABSTRACT:

Introduction

Objective response rates (ORR) appear to be higher in melanoma patients who develop immune-related adverse events (irAEs), but whether there is a similar association between irAEs and survival remains unknown.

Materials and methods

Patients with advanced melanoma treated with single-agent pembrolizumab or nivolumab in the province of Alberta from June 2014 to May 2017 were identified through the provincial pharmacy database. Chart review identified and categorized all irAEs that occurred while on anti-programmed cell death protein 1 (PD-1) checkpoint inhibitors. The primary objective was to compare overall survival (OS) with patients who developed any irAEs versus those who did not. Secondary outcomes included progression-free survival (PFS) and ORR.

Results<

SUBMITTER: Suo A 

PROVIDER: S-EPMC7216458 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature